Will World's Largest HCV Population Have Access To Newest Treatments?
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck will work with the Chinese Physician Association on an HCV awareness campaign.
You may also be interested in...
Merck/Roche Co-Promote Pact Attempts To Shut Vertex Out Of HCV Protease Inhibitor Space
Roche will co-promote Merck's Victrelis with its own HCV drugs Pegasys and Copegus in the U.S.
Merck Looks To Leverage "Next 10" For Growth: Emerging Markets Earnings Roundup (Part 4)
Emerging markets remained a key focus of Big Pharma during first quarter earnings calls. Merck & Co., which aims to see one-fourth of its revenue come from emerging markets by 2013, focused investment in best growth drivers and sales efficiency to bolster key products. Merck's emerging markets strategy will focus on maximizing its own brands, leveraging partnerships with low-cost makers and looking for "inter-brand" opportunities.
Mitsubishi Tanabe's Key Products And M&A Rumors Tempered By Management Issues
TOKYO - Mitsubishi Tanabe has industry observers scratching their heads. On one hand, the company has rights in Asia for telaprevir, a high-profile hepatitis C treatment, and its oral multiple sclerosis therapy Gilenya (fingolimod) recently gained approval in the U.S. through ex-Japan licensee Novartis and is on file for approval in Japan. But the company's repeated supply chain irregularities raise concern over management's ability to handle its manufacturing quality control process